Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector to advance rational drug repositioning and combination therapy based on translational bioinformatics and network pharmacology approaches and to explore opportunities for new public-private partnerships to facilitate drug rescue/repurposing and combination therapy.
Development of recommendations for rational repositioning and combination therapy development.
Development, negotiation, and implementation of appropriate agreements among the stakeholders involved in repositioning and combination therapy of drugs for AD and related dementias.
These agreements should address legal issues, intellectual property rights, and liability to expedite rigorous clinical testing of repurposed drugs.
- Research Implementation Area
- Public Private Partnerships
- In Progress
- PAR-20-156: Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer’s Disease (R01 Clinical Trial Optional)